Vaxcyte, Inc. (PCVX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Vaxcyte, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Vaxcyte, Inc. (PCVX) has returned 25.94% so far this year and 53.89% over the past 12 months.

Based on dividend-adjusted daily data since Jun 12, 2020, PCVX's average daily return is +0.14%, while the average monthly return is +2.55%. At this rate, your investment would double in approximately 2.3 years.

Historically, 51% of months were positive and 49% were negative. The best month was Oct 2022 with a return of +81.7%, while the worst month was Mar 2025 at -48.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, PCVX closed higher 50% of trading days. The best single day was Oct 24, 2022 with a return of +60.4%, while the worst single day was Mar 31, 2025 at -45.6%.

Vaxcyte, Inc. has an annualized alpha of 26.41%, beta of 0.84, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since June 15, 2020.

• This stock captured 174.90% of S&P 500 Index gains and 159.91% of its losses — amplifying both gains and losses, but participating more in upside than downside.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PCVX ranks 47 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Vaxcyte, Inc. (PCVX) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Vaxcyte, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vaxcyte, Inc. was 76.22%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current Vaxcyte, Inc. drawdown is 50.73%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Vaxcyte, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Vaxcyte, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.